Skip header and navigation

3 records – page 1 of 1.

A 3-month evaluation of the efficacy of nedocromil sodium in asthma: a randomized, double-blind, placebo-controlled trial of nedocromil sodium conducted by a Canadian multicenter study group.

https://arctichealth.org/en/permalink/ahliterature229565
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Publication Type
Article
Date
Mar-1990
Author
A S Rebuck
S. Kesten
L P Boulet
A. Cartier
D. Cockcroft
J. Gruber
F. Laberge
E. Lee-Chuy
M. Keshmiri
G F MacDonald
Author Affiliation
Edmonton General Hospital, Canada.
Source
J Allergy Clin Immunol. 1990 Mar;85(3):612-7
Date
Mar-1990
Language
English
Publication Type
Article
Keywords
Adult
Anti-Inflammatory Agents, Non-Steroidal - adverse effects - therapeutic use
Asthma - drug therapy - physiopathology
Canada
Chronic Disease
Double-Blind Method
Drug Therapy, Combination
Drug Tolerance
Female
Humans
Male
Middle Aged
Multicenter Studies as Topic
Nedocromil
Peak Expiratory Flow Rate - drug effects - physiology
Quinolones - adverse effects - therapeutic use
Randomized Controlled Trials as Topic
Time Factors
Abstract
Nedocromil sodium is a pyranoquinoline dicarboxylic acid derivative, formulated in a metered-dose inhaler. Because nedocromil sodium has in vitro and in vivo anti-inflammatory properties, it was evaluated in a group of steroid-dependent patients with asthma to observe how well it might be tolerated and for evidence of any beneficial effects. In a double-blind, group-comparative study, 127 patients received nedocromil sodium and 61 received placebo, administered as two puffs of 2 mg, four times per day, for 12 weeks. Ten patients developed adverse reactions, seven receiving active drug and three patients receiving placebo. Two patients of each group withdrew because of worsening asthma. Despite selecting patients whose asthma was stable, when they were receiving established therapeutic regimens that included steroids and bronchodilators, it was found that diary-card symptom scores, morning and evening peak expiratory flow rate values, and inhaled beta-agonist usage all demonstrated slight but significant benefit with addition of nedocromil sodium. It is concluded that the inhaled, anti-inflammatory agent, nedocromil sodium, may be added to asthma-treatment regimens with the reasonable expectation of further modest symptomatic benefit.
PubMed ID
2155958 View in PubMed
Less detail

Double-blind comparison of nedocromil sodium (1% nasal spray) and placebo in rhinitis caused by birch pollen.

https://arctichealth.org/en/permalink/ahliterature234676
Source
Clin Otolaryngol Allied Sci. 1987 Oct;12(5):365-70
Publication Type
Article
Date
Oct-1987
Author
P. Sipilä
M. Sorri
J. Pukander
Author Affiliation
Department of Otolaryngology, University of Oulu, Finland.
Source
Clin Otolaryngol Allied Sci. 1987 Oct;12(5):365-70
Date
Oct-1987
Language
English
Publication Type
Article
Keywords
Administration, Intranasal
Clinical Trials as Topic
Double-Blind Method
Humans
Nedocromil
Pollen
Quinolines - administration & dosage
Rhinitis, Allergic, Seasonal - drug therapy
Trees
Abstract
A double-blind parallel group study was undertaken during May and June 1985 to compare the effect of nedocromil sodium (1% nasal spray) and placebo, taken twice daily, in relieving the symptoms of rhinitis caused by birch pollen. Two centres were involved. The 54 patients studied had a history of rhinitis in 2 previous birch pollen seasons and positive skin tests to birch pollen. Patients were treated for 4 weeks, but to compare the effects of the 2 treatments the peak pollen periods were used. For dairy card symptoms, results in the 2 centres differed: in Tampere, there were trends in favour of nedocromil sodium with respect to itching (P = 0.04, sneezing (P = 0.06) and total symptoms (P = 0.09); in Oulu no significant differences were seen. Nasal peak expiratory flow rates were slightly better in the nedocromil sodium group. In respect of antihistamine usage, results in the 2 centres were similar and significantly more were used in the placebo group (P less than 0.01). At the end of the trial, both the patients' and the investigators' opinions of treatment effect favoured nedocromil sodium. There were no serious side effects. The results suggest that nedocromil sodium 1% nasal spray, when given twice daily, is effective in the treatment of seasonal allergic rhinitis.
PubMed ID
2827920 View in PubMed
Less detail

A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma.

https://arctichealth.org/en/permalink/ahliterature211139
Source
Clin Ther. 1996 Sep-Oct;18(5):939-52
Publication Type
Article
Author
P. Thomas
R N Ross
J R Farrar
Author Affiliation
University of Toronto, Division of Respirology, St. Michael's Hospital, Ontario, Canada.
Source
Clin Ther. 1996 Sep-Oct;18(5):939-52
Language
English
Publication Type
Article
Keywords
Administration, Inhalation
Adult
Anti-Asthmatic Agents - administration & dosage - economics - therapeutic use
Asthma - drug therapy - economics
Costs and Cost Analysis
Drug Prescriptions
Emergency Service, Hospital - utilization
Female
Forced expiratory volume
Health Care Costs
Humans
Male
Middle Aged
Nebulizers and Vaporizers - economics
Nedocromil - administration & dosage - economics - therapeutic use
Ontario
Peak Expiratory Flow Rate
Retrospective Studies
Abstract
A retrospective analysis of patient charts was performed for a single, multioffice pulmonary practice in Toronto, Ontario. Canada, to assess hospital care utilization and associated cost reductions after asthma prophylaxis with nedocromil sodium inhalation aerosol. Data were obtained from 310 adult patients with mild, moderate, or severe asthma who were treated in the practice between January 1988 and June 1994 and who had been placed on nedocromil sodium for at least 1 year. The number of office visits increased with nedocromil sodium therapy due to initial surveillance of the new medication, but no other changes were made in the usual protocol for each visit. After initiation of nedocromil sodium therapy, patients showed better asthma control as measured by improvements in pulmonary function scores and by reduced hospital utilization (both emergency department visits and hospital admissions). It is likely that the improvements in asthma control could result in cost savings, and savings projections for the Canadian health care system were made using the retrospective data collected for asthma-related hospital services. Prospective data are needed to confirm our findings.
PubMed ID
8930433 View in PubMed
Less detail